What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing?

Gabriele Bammer*, Wim Van Den Brink, Patrick Gschwend, Vincent Hendriks, Jürgen Rehm

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    22 Citations (Scopus)

    Abstract

    Following on from last edition's Harm Reduction Digest on drug consumption facilities this Digest investigates what can be learnt from the Swiss and Dutch trials of heroin prescribing about the unintended consequences of this controversial intervention to reduce heroin-related harm. The authors of the paper bring considerable experience in the implementation and evaluation of such schemes in Europe and their consideration in Australia. The paper systematically addresses concerns about heroin prescribing and suggests further research to respond to some unanswered questions
    Original languageEnglish
    Pages (from-to)363-371
    Number of pages9
    JournalDrug and Alcohol Review
    Volume22
    Issue number3
    DOIs
    Publication statusPublished - Sept 2003

    Fingerprint

    Dive into the research topics of 'What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing?'. Together they form a unique fingerprint.

    Cite this